Leyva, Sergio <br/><br/>
Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.  [electronic resource] 

 -  Clinical transplants  2010 
 - 369-82 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0890-9016 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Academies and Institutes<br/>Acute Disease<br/>Adult<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Drug Administration Schedule<br/>Female<br/>Graft Rejection--immunology<br/>Graft Survival--drug effects<br/>HLA Antigens--immunology<br/>Humans<br/>Immunity, Humoral--drug effects<br/>Immunosuppressive Agents--administration & dosage<br/>Isoantibodies--blood<br/>Kidney Transplantation--immunology<br/>Male<br/>Mexico<br/>Middle Aged<br/>Plasmapheresis<br/>Protease Inhibitors--administration & dosage<br/>Proteasome Endopeptidase Complex--metabolism<br/>Proteasome Inhibitors<br/>Pyrazines--administration & dosage<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult